Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.  |
AIDS TREATMENT NEWS "alert" March 18, 2004
John S. James
About 5% of patients have a potentially serious reaction to abacavir (Ziagen), and must discontinue the drug and never use it again. Now researchers in Australia have reported new data showing that testing for certain genes can accurately predict who will have this reaction.
In their cohort of 248 patients, 18 of whom had the reaction, a genetic test for HLA-B*5701 alone would reduced the risk of abacavir hypersensitivity from 8% to 0.4% -- but would result in about 1.6% of their patients being inappropriately denied the drug. Adding a second genetic test would reduce these false positive from 1.5% to 0.4%. These figures will vary by racial groups, or by geographic regions within the same race, because of the different genetic inheritance of different populations.
The researchers presented their findings at the Retroviruses conference (February 8-11, 2004 in San Francisco), and published a full report on March 15. They are now using the testing in their clinical practice, to avoid giving abacavir to patients who are likely to react to it. This testing is not in general use, however.
Incidentally, having HLA-B*5701 is probably an advantage overall, because it is associated with slower HIV progression.
For More Information
For an overview of presentations on this subject at the Retroviruses conference, see "Pharmacogenetics Predict Abacavir (Ziagen) Hypersensitivity" by Deborah Mitchell, published March 1, 2004 on the HIV and Hepatitis site:
http://www.hivandhepatitis.com/recent/nrtis/030102d.html
Original paper: Martin AM, Nolan D, Gaudieri S and others. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5.
040318
ATN040304
Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .